For a decade, thousands of PhDs in epigenetics may have been relying on the wrong tool as they study the biological processes that regulate how and when genes are expressed or silenced.
Researchers at Baylor College of Medicine and collaborating institutions have uncovered new potential therapeutic targets for cancer and new insights into existing cancer drug targets.
